Novella Clinical Expands West Coast Business Development Team

Novella Clinical Expands West Coast Business Development Team

RESEARCH TRIANGLE PARK, N.C., May 1, 2013 - Novella Clinical, a full service clinical research organization (CRO), today announced two new hires to supplement business development efforts on the west coast. Joining as Directors of Client Business Development are Carole Gabos and Jeremie Braun.

Carole Gabos has more than 20 years of experience working with small and mid-size biopharmaceutical companies. She is rejoining Novella, having served in a business development role for the company in the early 2000s. Since that time she has worked with both large and small CROs. Carole holds a Bachelor of Science degree from University of Dayton and is based in California.

Also joining is Jeremie Braun, who most recently served as a manager of business development for a cardiac safety services company. With over a decade of dedicated sales to western U.S. biopharmaceutical companies, he is also experienced in medical device and diagnostic services. Jeremie earned a Bachelor of Science degree from University of California, Santa Barbara, and remains based in southern California.

"The western U.S. has long been one of the strongest geographic areas for Novella, and is home to a vast number of biopharmaceutical companies who, like, Novella, value flexibility and transparency in the clinical development process," said Novella Clinical Executive Vice President Nick Dyer. "The addition of Carole and Jeremie will help us to capture even more of the clinical trial outsourcing market and help bring valuable compounds through the development process."

About Novella Clinical
Novella Clinical, Inc. is a full service clinical research organization with dual headquarters in Research Triangle Park, N.C and Stevenage, England. Celebrating its 15th anniversary, Novella serves as an active partner to the oncology, biopharma and medical device industries. As the first global eCRO, Novella integrates deep clinical expertise with industry-leading technologies and a proven approach to support, streamline and expertly resource the entire product development process. For more information, visit

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.